Cosmos Group Holdings Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Cosmos Group Holdings Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $6.4K | Apr 15, 2025 |
| FY2023 | Dec 31, 2023 | $618.2K | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | $14.06M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $9.32M | Dec 7, 2023 |
| FY2021 | Dec 31, 2020 | $4.36M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $671.3K | Jun 25, 2021 |
| FY2018 | Dec 31, 2018 | $733.2K | Mar 28, 2019 |
| FY2018 | Dec 31, 2017 | $773.5K | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $443.8K | Mar 23, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $5.51M | Dec 7, 2023 |
| FY2022 | Dec 31, 2021 | $2.43M | Dec 7, 2023 |
| FY2020 | Dec 31, 2020 | $90.5K | Jun 25, 2021 |
| FY2020 | Dec 31, 2019 | $671.3K | Jun 25, 2021 |
| FY2019 | Dec 31, 2018 | $733.2K | Apr 29, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $2.6K | Apr 15, 2025 |
| FY2023 | Dec 31, 2023 | $232.0K | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | $11.04M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $8.30M | Dec 7, 2023 |
| FY2021 | Dec 31, 2020 | $3.52M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $101.1K | Jun 25, 2021 |
| FY2019 | Dec 31, 2018 | $130.4K | Apr 29, 2020 |
| FY2018 | Dec 31, 2017 | $263.3K | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $154.4K | Mar 23, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $4.69M | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | ($77.34M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($101.67M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($25.03M) | Dec 7, 2023 |
| FY2021 | Dec 31, 2020 | $467.7K | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($683.5K) | Jun 25, 2021 |
| FY2019 | Dec 31, 2018 | $5.8K | Apr 29, 2020 |
| FY2018 | Dec 31, 2017 | ($127.6K) | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $19.2K | Mar 23, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($276.5K) | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | ($10.69M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($96.67M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($24.09M) | Dec 7, 2023 |
| FY2020 | Dec 31, 2020 | ($260.0K) | Jun 25, 2021 |
| FY2020 | Dec 31, 2019 | ($679.5K) | Jun 25, 2021 |
| FY2019 | Dec 31, 2018 | ($109.3K) | Apr 29, 2020 |
| FY2018 | Dec 31, 2017 | ($110.8K) | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $23.3K | Mar 23, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $867.2K | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | $26.90M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $9.22M | Dec 7, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Apr 15, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($3.54M) | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | ($542.7K) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $2.95M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($4.88M) | Dec 7, 2023 |
| FY2021 | Dec 31, 2020 | ($3.95M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($279.8K) | Jun 25, 2021 |
| FY2019 | Dec 31, 2018 | ($667.0K) | Apr 29, 2020 |
| FY2018 | Dec 31, 2017 | ($297.3K) | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $43.9K | Mar 23, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2022 | $2.9K | Apr 16, 2024 |
| FY2021 | Dec 31, 2021 | $5.3K | Apr 15, 2022 |
| FY2021 | Dec 31, 2020 | $229.1K | Apr 15, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $43.3K | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $18.65M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $39.11M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $42.60M | Dec 7, 2023 |
| FY2021 | Dec 31, 2020 | $15.26M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $172.1K | Jun 25, 2021 |
| FY2019 | Dec 31, 2018 | $150.0K | Apr 29, 2020 |
| FY2018 | Dec 31, 2017 | $473.8K | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $172.0K | Mar 23, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $41.27M | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $65.45M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $32.72M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $22.83M | Dec 7, 2023 |
| FY2021 | Dec 31, 2020 | $15.27M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $561.8K | Jun 25, 2021 |
| FY2019 | Dec 31, 2018 | $251.8K | Apr 29, 2020 |
| FY2018 | Dec 31, 2017 | $586.7K | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $136.6K | Mar 23, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($41.23M) | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | ($46.81M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $6.40M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $19.65M | Dec 7, 2023 |
| FY2021 | Dec 31, 2020 | ($250.8K) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($389.8K) | Jun 25, 2021 |
| FY2020 | Dec 31, 2018 | ($101.8K) | Jun 25, 2021 |
| FY2019 | Dec 31, 2017 | ($112.9K) | Apr 29, 2020 |
| FY2018 | Dec 31, 2016 | $35.4K | Mar 28, 2019 |
| FY2017 | Dec 31, 2015 | $16.2K | Mar 23, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($200.76M) | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | ($205.45M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($128.11M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($26.44M) | Dec 7, 2023 |
| FY2021 | Dec 31, 2020 | ($1.38M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($806.8K) | Jun 25, 2021 |
| FY2019 | Dec 31, 2018 | ($123.3K) | Apr 29, 2020 |
| FY2018 | Dec 31, 2017 | ($129.1K) | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $24.4K | Mar 23, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $43.3K | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $22.9K | Apr 15, 2025 |
| FY2021 | Dec 31, 2021 | $1.13M | Apr 15, 2022 |
| FY2021 | Dec 31, 2020 | $773.4K | Apr 15, 2022 |
| FY2021 | Dec 31, 2019 | $445.1K | Apr 15, 2022 |
| FY2020 | Dec 31, 2018 | $12.1K | Jun 25, 2021 |
| FY2019 | Dec 31, 2017 | $99.6K | Apr 29, 2020 |
| FY2018 | Dec 31, 2016 | $1.6K | Mar 28, 2019 |
| FY2017 | Dec 31, 2015 | $4.1K | Mar 23, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Dec 7, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Apr 15, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Dec 7, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Apr 15, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 4.59B | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | 1.93B | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 454.40M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | 358.07M | Dec 7, 2023 |
| FY2021 | Dec 31, 2020 | 333.91M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | 21.54M | Jun 25, 2021 |
| FY2019 | Dec 31, 2018 | 21.49M | Apr 29, 2020 |
| FY2018 | Dec 31, 2017 | 21.49M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | 10.96M | Mar 23, 2018 |